SGHERZA, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 993
AS - Asia 727
EU - Europa 671
SA - Sud America 192
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.622
Nazione #
US - Stati Uniti d'America 962
IT - Italia 343
SG - Singapore 307
BR - Brasile 146
CN - Cina 125
HK - Hong Kong 106
RU - Federazione Russa 85
VN - Vietnam 65
SE - Svezia 49
DE - Germania 48
FR - Francia 42
GB - Regno Unito 30
BD - Bangladesh 24
IN - India 18
AR - Argentina 17
CI - Costa d'Avorio 14
CA - Canada 13
ID - Indonesia 13
FI - Finlandia 12
TR - Turchia 11
NL - Olanda 10
AT - Austria 9
BE - Belgio 9
MX - Messico 9
JP - Giappone 8
CO - Colombia 7
IQ - Iraq 7
PK - Pakistan 7
PL - Polonia 7
UZ - Uzbekistan 7
IE - Irlanda 6
CL - Cile 5
EC - Ecuador 5
KR - Corea 5
MA - Marocco 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
JM - Giamaica 4
PE - Perù 4
TN - Tunisia 4
UA - Ucraina 4
VE - Venezuela 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
EG - Egitto 3
ES - Italia 3
PH - Filippine 3
PY - Paraguay 3
TW - Taiwan 3
EU - Europa 2
NI - Nicaragua 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
IL - Israele 1
KZ - Kazakistan 1
LS - Lesotho 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 2.622
Città #
Singapore 174
Ashburn 159
San Jose 114
Hong Kong 86
Milan 81
Beijing 57
Fairfield 46
Chandler 43
Nyköping 42
Los Angeles 32
New York 32
Bari 29
Seattle 29
Woodbridge 29
Ho Chi Minh City 24
Houston 24
Columbus 22
Santa Clara 19
Rome 18
Wilmington 18
Lauterbourg 17
Falkenstein 15
Abidjan 14
Ann Arbor 14
Cambridge 14
Boardman 13
Frankfurt am Main 13
Figino 11
Hanoi 11
Jakarta 11
Lawrence 11
London 11
São Paulo 11
Helsinki 10
Inglewood 10
Brussels 9
Buffalo 9
Des Moines 9
Dallas 8
Roxbury 8
Council Bluffs 7
Gesualdo 7
Moscow 7
Munich 7
Naples 7
Nuremberg 7
Tashkent 7
Atlanta 6
Brooklyn 6
Salt Lake City 6
San Francisco 6
Vienna 6
Chennai 5
Chicago 5
Florianópolis 5
Johannesburg 5
Miano 5
San Diego 5
Warsaw 5
Alcamo 4
Bitonto 4
Denver 4
Dublin 4
Florence 4
Imbersago 4
Istanbul 4
Modugno 4
Montreal 4
Orem 4
Palermo 4
Paris 4
Phoenix 4
Princeton 4
Seoul 4
Tokyo 4
Avellino 3
Baku 3
Belo Horizonte 3
Bengaluru 3
Birmingham 3
Bắc Ninh 3
Casablanca 3
Chiswick 3
Da Nang 3
Guangzhou 3
Hải Dương 3
Las Vegas 3
Magé 3
Padua 3
Phú Thọ 3
Roubaix 3
Taranto 3
Verona 3
Washington 3
Andria 2
Aparecida de Goiânia 2
Bauru 2
Belford Roxo 2
Betim 2
Bisceglie 2
Totale 1.554
Nome #
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 206
Challenges and opportunities of MicroRNAs in lymphomas 146
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 134
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 121
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 110
What Is New in the Treatment of Smoldering Multiple Myeloma? 109
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 100
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 99
null 96
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 93
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 88
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 87
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 87
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 82
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy 77
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 73
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 72
Dasatinib first-line: Multicentric Italian experience outside clinical trials 72
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials 69
null 68
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 67
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 65
Implications of interleukin-6 (Il-6)-blockade for severe covid-19 infection in patients with multiple myeloma 62
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 61
Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments 57
Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review 56
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese” 55
Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study 51
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia 48
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry 48
Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: “Chance or Causality?” 46
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease 43
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 42
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese 29
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 6
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA‐EPIFLUEHA Report 3
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia 3
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 3
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study 3
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 3
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 3
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 3
Totale 2.746
Categoria #
all - tutte 11.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.768


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022120 21 8 0 8 6 9 14 5 5 7 21 16
2022/2023139 14 29 14 7 5 16 4 24 20 0 6 0
2023/2024186 26 31 26 8 15 28 28 5 0 0 6 13
2024/2025591 22 7 30 24 16 71 69 57 21 17 104 153
2025/20261.419 183 58 90 132 175 66 107 36 206 168 44 154
2026/202778 78 0 0 0 0 0 0 0 0 0 0 0
Totale 2.746